Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Role of hyperhomocysteinemia in atherothrombotic vascular disease
2004-003703-21Phase 3Completed
- Sponsor
- Semmelweis University
- Start
- Nov 2004
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of folic acid and ascorbic acid in atherothrombosis and hyperhomocysteinemia, sponsored by Semmelweis University. Primary endpoints: Endothelial-dependent and -independent vasodilation and Pulse wave velocity. Started Nov 2004; status: completed.
02
Drugs
folic acidascorbic acid
03
Conditions
atherothrombosishyperhomocysteinemia
Beyond the preview
Go deeper on 2004-003703-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003703-21.